fullsizerender-3

nehi2

Patients in need of cholesterol lowering therapy are not being granted access to it, according to a novel data analysis by the Familial Hypercholesterolemia Foundation. (PRNewsfoto/The FH Foundation)

FH Foundation’s FOCUS analysis shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates

1 Comment

Pasadena, Calif. – The Familial Hypercholesterolemia Foundation today published a study in Circulation revealing high rejection rates for PCSK9 inhibitors in the two at-risk patient populations approved for this novel cholesterol-lowering class of therapy.

The FH Foundation’s FOCUS (FH Optimal … Read More


sweeney_colleen_20150410_np_fh_880-ssedit

mccready_colleen_20150410_np_fh_751

screen-shot-2017-04-05-at-1-45-22-pm

screen-shot-2017-03-30-at-10-34-57-am

img_5403

1

New Collaboration Improves Access to Treatment for Familial Hypercholesteremia (FH) Patients Most at Risk for Early Heart Attacks and Death

2 Comments

In collaboration with The FH Foundation, Express Scripts expands access to PCSK9 inhibitors for those with FH.

PASADENA, Calif., March 15, 2017 /PRNewswire-USNewswire/ — The FH Foundation, a patient-centered non-profit dedicated to research, advocacy, and education of all forms of familial … Read More


shutterstock_254940166-converted-01

Clinical Trials

No Comments

Understanding Clinical Trials

Therapies are developed by researchers at academic and government research institutions, and pharmaceutical companies. First, they are tested in animals to understand safety risks (those are called Pre-Clinical Trials). The next step is to study the therapies in … Read More


1 2 3 15